Advertisement
Advertisement
U.S. markets open in 3 hours 29 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Yumanity Therapeutics, Inc. (YMTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.5500+0.1100 (+3.20%)
At close: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close3.4400
Open3.3800
Bid0.0000 x 1200
Ask0.0000 x 4000
Day's Range3.3800 - 3.7034
52 Week Range2.8300 - 26.2000
Volume116,142
Avg. Volume227,790
Market Cap36.595M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-7.8120
Earnings DateNov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for YMTX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Yumanity Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 12/07/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • GlobeNewswire

    Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the grant to 1 employee of non-statutory stock options for the purchase of up to an aggregate of 2,000 shares of Yumanity’s common stock. The options will vest over four years, with 25 percent of the shares vesting on the first anniversary of th

  • GlobeNewswire

    Yumanity Therapeutics to Present at Multiple Upcoming November Investor Conferences

    BOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will be presenting at the following investor conferences in November. He will discuss the results of the recently completed Phase 1b study of YTX-7739 in patients with Park

  • GlobeNewswire

    Yumanity Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

    Announced Successful Phase 1b trial for YTX-7739 in Parkinson’s disease patients; YTX-7739 was well tolerated and demonstrated target engagement and favorable PK/PD and safety profiles Company anticipates initiating Phase 2 clinical trial of YTX-7739 in patients with Parkinson’s disease in 2022 Appointed Michael D. Wyzga as SVP, Chief Financial Officer BOSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discove

Advertisement
Advertisement